Nature Mental Health
May 1, 2026
Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 1, 2026
Daniel Bello, J. Connolly, Jean Addington et al.
BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...
Biological psychiatry. Cognitive neuroscience and neuroimaging
January 18, 2025
Brian J Roach, Judith M. Ford, Spero Nicholas et al.
7 citations
Auditory steady-state response (ASSR) abnormalities in the 40-Hz (gamma band) frequency have been observed in schizophrenia and in rodent studies of NMDA receptor (NMDAR) hypofunction. However, the extent to which 40-Hz ASSR abnormalities in schizophrenia resemble deficits in 40-Hz ASSR induced by acute administration of ketamine, an NMDAR antagonist, is not yet known. To address this knowledge...
Schizophrenia Research
August 25, 2022
Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...
medRxiv Preprint Server
August 31, 2020
Steven Pennybaker, Brian J Roach, Susanna L Fryer et al.
preprint
Background Ketamine is a rapid-acting treatment for patients with treatment refractory depression (TRD), however treatment responses are often transient and ketamine’s antidepressant action lacks robust clinical durability. Little is known about which patient characteristics are associated with faster or more durable ketamine responses. Ketamine’s antidepressant mechanism is proposed to involve...
medRxiv Preprint Server
April 10, 2020
Chadi G. Abdallah, Kyung-Heup Ahn, Lynnette A. Averill et al.
1 citation
preprint
Over the past decade, various N-Methyl-D-Aspartate modulators have failed in clinical trials, underscoring the challenges of developing novel rapid-acting antidepressants based solely on the receptor or regional targets of ketamine. Thus, identifying the effect of ketamine on the brain circuitry and networks is becoming increasingly critical. In this longitudinal functional magnetic resonance...
Psychotherapy and Psychosomatics
2016
Stuart J. Eisendrath, Erin P Gillung, Kevin L. Delucchi et al.
193 citations
BACKGROUND: Due to the clinical challenges of treatment-resistant depression (TRD), we evaluated the efficacy of mindfulness-based cognitive therapy (MBCT) relative to a structurally equivalent active comparison condition as adjuncts to treatment-as-usual (TAU) pharmacotherapy in TRD. METHODS: This single-site, randomized controlled trial compared 8-week courses of MBCT and the Health...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
August 2015
Jose Cortes-Briones, Patrick D Skosnik, Daniel Mathalon et al.
Gamma (γ)-band oscillations play a key role in perception, associative learning, and conscious awareness and have been shown to be disrupted by cannabinoids in animal studies. The goal of this study was to determine whether cannabinoids disrupt γ-oscillations in humans and whether these effects relate to their psychosis-relevant behavioral effects. The acute, dose-related effects of...
BMC Complementary and Alternative Medicine
March 11, 2014
Stuart J. Eisendrath, Erin P Gillung, Kevin L. Delucchi et al.
BackgroundMajor depressive disorder (MDD) is the leading cause of disability in the developed world, yet broadly effective treatments remain elusive. Up to 40% of patients with depression are unresponsive to at least two trials of antidepressant medication and thus have “treatment-resistant depression” (TRD). There is an urgent need for cost-effective, non-pharmacologic, evidence-based...
Yunong Bai, Simon Vandekar, Brandee Feola et al.
Abstract Objective Tobacco and cannabis are the most used substances among individuals at clinical high risk for psychosis (CHR-P), but it remains controversial whether substance use drives symptom exacerbation and psychosis transition, or vice versa. We investigated longitudinal dose-response relationships of tobacco and cannabis use with clinical presentation in a CHR-P population. Methods...